CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
Total Raised
$180M
$430M
Celea TherapeuticsOllin Biosciences
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
2023
Boston, MA
HQ
Chicago, Illinois
Private
Status
Private
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and Ollin Biosciences.